Physician profile
Charles Grayson
NPI 1053780502
$463.51
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $421 · 2022: $42.60.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $186.29 | 2021-2022 | |
| Pfizer INC. | $47.90 | 2021 | |
| Amgen INC. | $45.17 | 2021 | |
| Glaxosmithkline, LLC. | $38.46 | 2021 | |
| Astellas Pharma US INC | $20.85 | 2021 | |
| Novartis Pharmaceuticals Corporation | $20.10 | 2021 | |
| Novo Nordisk INC | $19.13 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.81 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.64 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.58 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.68 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.17 | 2021 | |
| Amarin Pharma, INC. | $11.73 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Grayson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.